Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream

The goal of this non-interventional study is to assess changes in the signs and symptoms of Chronic Hand Eczema (CHE), as well as the safety profile and use of delgocitinib cream in routine clinical practice, over a 52-week observation period. The main question it aims to answer is: Does delgocitinib cream show effectiveness in routine clinical practice in adult patients with moderate to severe Chronic Hand Eczema (CHE), as measured by achievement of a modified Physician Global Assessment (mPGA) score of 0 or 1? The decision to prescribe delgocitinib cream is made by the treating physician, as part of the participant's routine medical care for CHE.

NCT Number	NCT07603193
Lead Sponsor	LEO Pharma Collaborators: Optimapharm, ICON Clinical Research, IQVIA Inc., Vivactis M2Research
Conditions	Chronic Hand Eczema (CHE)
Enrollment	1,000 participants
Start Date	2025-06-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-22